Having validated FOLR1 surface expression in U-2 OS, we evaluated the antitumor activity of FH FOLR1-CART by co-culturing tumor cells with CD8+ FH FOLR1-CART or NT T cells at various E:T ratios ranging from 10:1 to 1:1. Here, CD8A is linked to neoplasm.